Biotech 2050 Podcast cover image

Leading personalized immune medicines, Harlan Robins, CSO & Co-Founder, Adaptive Biotechnologies

Biotech 2050 Podcast

00:00

Genentech's Personalized Cancer Therapy

Harlan: We're in a 800 people person range. And we have different parts to our company that are sort of in different stages. Our big clinical product was for diagnosing blood cancers, which are cancers of your these T and B cells that are the adaptive immune cells can become cancerous. So our same technology can be used for monitoring them. The other big area we're working on is in the auto immune space where we're identifying what the immune system is specifically targeting so that we can develop therapies to block that target.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app